Is Dyne Therapeutics Inc (NASDAQ: DYN) A Stock A New Investor Should Consider Now?

Dyne Therapeutics Inc (NASDAQ:DYN) shares, rose in value on Thursday, April 04, with the stock price down by -3.34% to the previous day’s close as strong demand from buyers drove the stock to $27.80.

Actively observing the price movement in the recent trading, the stock is buoying the session at $28.76. The value of beta (5-year monthly) is 0.95. Referring to stock’s 52-week performance, its high was $30.27, and the low was $6.40. On the whole, DYN has fluctuated by 7.46% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

With the market capitalization of Dyne Therapeutics Inc currently standing at about $2.25 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 09, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.8, which is expected to increase to -$0.7 for fiscal year -$3.27 and then to about -$3.17 by fiscal year 2025. Data indicates that the EPS growth is expected to be 17.20% in 2025, while the next year’s EPS growth is forecast to be 3.10%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that DYN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of DYN currently trading nearly 1.66% and 12.98% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.59, while the 7-day volatility ratio is showing 6.99% which for the 30-day chart, stands at 7.38%. Furthermore, Dyne Therapeutics Inc (DYN)’s beta value is 0.95, and its average true range (ATR) is 1.89.

A comparison of Dyne Therapeutics Inc (DYN) with its peers suggests the former has fared considerably weaker in the market. DYN showed an intraday change of -3.34% in today’s session so far, and over the past year, it grew by 151.58%%.

Data on historical trading for Dyne Therapeutics Inc (NASDAQ:DYN) indicates that the trading volumes over the past 10 days have averaged 1.37 million and over the past 3 months, they’ve averaged 1.95 million. According to company’s latest data on outstanding shares, there are 61.47 million shares outstanding.

Nearly 38.45% of Dyne Therapeutics Inc’s shares belong to company insiders and institutional investors own 52.82% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.82 million shares as on Mar 15, 2024, resulting in a short ratio of 3.94. According to the data, the short interest in Dyne Therapeutics Inc (DYN) stood at 8.32% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 7.25 million. The stock has risen by 109.02% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DYN stock heading into the next quarter.